In a final step, we examined the effects of various JAK-2-targeting drugs and STAT5-targeting drugs on the growth and survival of primary mononuclear cells (MNC) obtained from the BM of patients with MPN. The gene discussed is STAT5A; the disease is myeloproliferative neoplasm.